Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors

Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors

Abstract Background Acquired drug resistance is the greatest obstacle to the successful treatment of multiple myeloma (MM). Despite recent advanced treatment options such as liposomal formulations, proteasome inhibitors, immunomodulatory drugs, myeloma-targeted antibodies, and histone deacetylase in...

Full description

Bibliographic Details
Main Authors: Joel G. Turner, Jana L. Dawson, Steven Grant, Kenneth H. Shain, William S. Dalton, Yun Dai, Mark Meads, Rachid Baz, Michael Kauffman, Sharon Shacham, Daniel M. Sullivan
Format: Article
Language:English
Published: BMC 2016-08-01
Series:Journal of Hematology & Oncology
Subjects:
Acquired drug resistance
Liposomal doxorubicin
Multiple myeloma
Mouse models
Relapsed/refractory myeloma
XPO1 inhibition
Online Access:http://link.springer.com/article/10.1186/s13045-016-0304-z

Internet

http://link.springer.com/article/10.1186/s13045-016-0304-z

Similar Items